Effect of Saraswata Ghrita through nasal route in Alzheimers disease on biochemical parameters.

Evaluation of add on effect of Saraswata Ghrita through Nasya in Alzheimer’s Disease on biochemical parameters – A Randomized Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052567

Enrollment

Registered

2023-05-12

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G308- Other Alzheimers disease

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients between the age group of 50 to 80 years. 2)Patients of both genders. 3)Diagnosed case of AD as per DSM IV criteria

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Revalidation of SMP of Saraswata Ghrita(SG) by following standard operating procedures. Evaluation of effect of SaraswataGhrita(SG) given through Nasya(nasal) on the basis of biochemical parameters related to Alzheimer’s disease.i;e •Tau phosphorylated at threonine 181 (p-tau181),Serotonin (sample will be taken between 9am -10am),Dopamine,Acetylcholine,DHEA (Dehydroepiandrosterone),Serum ferritin,S. calcium,Vit.B12,Folate,Vit. D,CBC, ESR, LFT, KFT Timepoint: assessment will be at base line i;e zero day and at 90th day	—

Measure

Time frame

Revalidation of SMP of Saraswata Ghrita(SG) by following standard operating procedures. Evaluation of effect of SaraswataGhrita(SG) given through Nasya(nasal) on the basis of biochemical parameters related to Alzheimer’s disease.i;e •Tau phosphorylated at threonine 181 (p-tau181),Serotonin (sample will be taken between 9am -10am),Dopamine,Acetylcholine,DHEA (Dehydroepiandrosterone),Serum ferritin,S. calcium,Vit.B12,Folate,Vit. D,CBC, ESR, LFT, KFT Timepoint: assessment will be at base line i;e zero day and at 90th day

—

Secondary

Measure	Time frame
Clinical efficacy on the basis of ADAS scale for Alzheimer’s disease and assessment of quality of life of Alzheimer’s disease patients on QoL scale. Timepoint: at base line(zero day), 1month, 2month, 3month	—

Countries

India

Contacts

Public ContactDr Robin Badal

ALL INDIA INSTITUTE OF AYURVEDA

drpramod88@gmail.com8930625596

Outcome results